| Domain | Best-supported finding | Evidence level |
|---|---|---|
| Disease identifier | Neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction; MONDO:0859304; LETM1 is the associated gene (pqac-00000000) | Curated disease-gene resource |
| Core cohort | Defining report identified 18 affected individuals from 11 unrelated families with bi-allelic LETM1 variants (pqac-00000005, pqac-00000004) | Human clinical primary study |
| Inheritance | Autosomal recessive disease caused by biallelic LETM1 variants; 67% of families reportedly consanguineous (pqac-00000005, pqac-00000008) | Human genetic evidence |
| Onset/course | Infantile onset in 78% (14/18) and early childhood onset in 22% (4/18); progression ranged from rapid to slow, with regression common (pqac-00000005, pqac-00000002) | Human clinical primary study |
| Major phenotypes | Global developmental delay 94%, optic atrophy 83%, sensorineural hearing loss 78%, cerebellar ataxia 78%, epilepsy 67%, spasticity 53%, myopathy 50%, cataracts 42-45%, cardiomyopathy 36%, diabetes 27% (pqac-00000006, pqac-00000008) | Human clinical primary study |
| Mortality/prognosis | 9/18 died, ages 2 months to 8 years; overall spectrum ranges from early lethal infantile disease to survival into adulthood with major disability (pqac-00000005, pqac-00000003) | Human clinical primary study |
| Diagnostic findings | Respiratory chain enzyme deficiencies in all tested individuals; elevated lactate 8/12; abnormal urine organic acids 9/11 including 3-methylglutaconic acid in 5/11; MRI often showed optic pathway atrophy and infratentorial abnormalities; muscle biopsy often showed COX-deficient/ragged-red fibers; EMG/NCS showed neurogenic and myopathic changes (pqac-00000003, pqac-00000008) | Human clinical/laboratory evidence |
| Molecular diagnosis | Exome sequencing with segregation/Sanger confirmation was used in the defining cohort; disease should be distinguished from contiguous 4p16.3 deletion disorders such as Wolf-Hirschhorn syndrome (pqac-00000008, pqac-00000004) | Human diagnostic implementation |
| Functional disease evidence | Patient fibroblasts/muscle and yeast assays showed disturbed mitochondrial morphology, reduced membrane potential, OXPHOS defects, and impaired K+/H+ exchange; nigericin rescue supported an osmotic/cation-homeostasis defect (pqac-00000002, pqac-00000001, pqac-00000016) | Human cells + model systems |
| Mechanism summary | Best-supported model is LETM1-dependent inner-membrane cation/osmotic homeostasis, especially K+/H+ exchange, required for mitochondrial volume control, cristae integrity, and OXPHOS maintenance; however, LETM1 ion-substrate assignment remains debated because Ca2+/H+ transport has also been proposed and TMBIM5 was identified as the principal mammalian mitochondrial Ca2+/H+ antiporter (pqac-00000009, pqac-00000010, pqac-00000011) | Mixed human, cellular, structural, model evidence |
| Therapy/trials | No disease-specific therapy and no LETM1-specific interventional trial were identified; management is currently supportive and symptom-directed (pqac-00000008) | Evidence of absence from available clinical sources |


*Table: This compact table summarizes the strongest currently available evidence for LETM1-related childhood-onset neurodegeneration, including identifiers, core cohort facts, phenotype frequencies, diagnostics, mechanism, and treatment status. It is useful as a quick-reference evidence snapshot for a disease knowledge base.*